Paul Sorajja

Dr. Paul Sorajja is an interventional cardiologist at Banner Health in Phoenix, Arizona. He received his medical degree from Mayo Medical School and completed his internal medicine residency and cardiology fellowship at the Mayo Graduate School of Medicine. He joined the Mayo Clinic staff in 2006, was promoted to professor of medicine in 2012, joined the Minneapolis Heart Institute in 2013 and moved to Banner Health in 2025.

Dr. Sorajja’s clinical practice focuses on catheter-based therapies for valvular and structural heart disease. He was part of the team that performed the first transcatheter mitral valve replacement in the United States for native mitral regurgitation in 2015 and has one of the highest worldwide case volumes in transcatheter mitral valve replacement. He has served as global or national principal investigator for numerous early feasibility and pivotal valve-disease trials, including the TRILUMINATE pivotal trial, the first randomized trial of tricuspid valve therapy published in the New England Journal of Medicine.

He is known for leading many first‑in‑human structural heart interventions, including early use of TriClip, MitraClip laceration techniques, dedicated TMVR in severe mitral annular calcification, vDyne technology and MitraClip for hypertrophic cardiomyopathy. Dr. Sorajja has authored more than 500 manuscripts and book chapters and is recognized for his expertise in cardiac hemodynamics, clinical education, hypertrophic cardiomyopathy and percutaneous structural heart interventions.

He has held leadership roles in multiple national societies and is a founding board member of the Cardiovascular Innovations Foundation. An editor‑in‑chief for several textbooks on cardiac catheterization, including a structural heart disease atlas, he has also served as program director for interventional cardiology fellowships and has received awards for medical education, including the Robert G. Hauser Award for Leadership Excellence in Innovation from the Minneapolis Heart Institute Foundation in 2017. Dr. Sorajja remains highly active in intellectual property development and start‑up ventures in cardiovascular innovation.